AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01591668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Study NCT01591668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Study NCT02814097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
Study NCT02814097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Study NCT00498433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg tablet once daily
Study NCT00498433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5 mg capsule once daily
Study NCT00498433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Aliskiren
Description: Matching placebo of aliskiren 300 mg tablet
Study NCT00498433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Aliskiren
Description: Matching placebo of aliskiren 300 mg tablet
Study NCT00498433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of amlodipine
Description: Matching placebo of amlodipine 5 mg capsule
Study NCT04672499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 300 mg tablets
Description: Miricorilant 300 mg tablets for oral administration
Study NCT04672499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 150 mg tablets
Description: Miricorilant 150 mg tablets for oral administration
Study NCT04672499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 150 mg tablets
Description: Placebo to match miricorilant 150 mg tablets for oral administration
Study NCT02812628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPR
Description: Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
Study NCT02812628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAPR-TILT
Description: Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
Study NCT00700947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (TOPROL-XL® )
Description: Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
Study NCT02324309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531
Study NCT02324309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix 75/25
Study NCT02324309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin R U-500
Study NCT02536547 — intervention group
Intervention type: DEVICE
Intervention: VAP
Description: all patients with suspected VAP : biochemestry microbiology lung ultrasound
Study NCT04838145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin + Pleconaril
Description: Randomized to treatment with study drugs (ribavirin and pleconaril)
Study NCT04838145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Randomized to treatment with placebo
Study NCT04199676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glucose tolerance test
Description: Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
Study NCT03739190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NRL Condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
Study NCT03739190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NRL Condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
Study NCT01165502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: MAD study with repeated subcutaneous (sc) doses
Study NCT01165502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for compound CM3.1-AC100 s.c.
Study NCT03342170 — intervention group
Intervention type: GENETIC
Intervention: G20210A prothrombin gene mutation and Factor 5 Leiden mutation
Description: blood sample
Study NCT02445183 — intervention group
Intervention type: OTHER
Intervention: None, N/A
Study NCT01394783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miller laryngoscope
Description: Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
Study NCT01394783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Storz videolaryngoscope
Description: Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
Study NCT04665778 — intervention group
Intervention type: OTHER
Intervention: hospital bedroom booking
Description: Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
Study NCT03962478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent and high-intensity focused ultrasound ablation system
Description: Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
Study NCT03962478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: Self-expandable biliary nitinol alloys stent
Study NCT03552237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fiber
Description: We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
Study NCT00937456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopically-assisted esophagectomy
Description: To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
Study NCT00937456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopically-assisted esophagectomy
Description: To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
Study NCT04265911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772 (subcutaneous)
Description: Subcutaneous injection
Study NCT04265911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772 (intramuscular)
Description: Intramuscular injection
Study NCT04265911 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23 (subcutaneous)
Description: Subcutaneous injection
Study NCT04265911 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23 (intramuscular)
Description: Intramuscular injection
Study NCT03116672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one dose ketorolac 10 mg
Description: Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
Study NCT03116672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One dose Diclofenac
Description: Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
Study NCT03116672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Administration of Placebo, 15 minutes before the clinical procedure.
Study NCT01877551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tauroursodeoxycholic acid
Description: The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
Study NCT01877551 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
Study NCT03248713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone 600mg 2 tablets will be compared to the placebo
Study NCT03248713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo sugar 2 tablets will be compared to mifepristone
Study NCT00553605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen 100mg
Description: Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
Study NCT00553605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib 40mg
Description: Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
Study NCT02358213 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound examinations are done 5 times
Study NCT02017132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate extract
Study NCT04664985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucogyne® ovule
Description: hyaluronic acid, vaginal ovule
Study NCT01885936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
Study NCT01885936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
Study NCT04563247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IgG SARS CoV 2 antibodies
Description: The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
Study NCT04157959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1
Description: Tablet,dose1,QD
Study NCT04157959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat dose2
Description: Tablet,dose2,QD
Study NCT00797511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TdcP-IPV vaccine
Description: 0.5 mL, Intramuscular
Study NCT00001077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamin and mineral supplements
Description: Oral tablets taken daily
Study NCT00001077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Peptamen
Description: Solution received daily
Study NCT00001077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: NuBasics
Description: Solution or dietary bar received daily
Study NCT04503837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Mobile Phone Video Recording
Description: Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
Study NCT03461211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
Study NCT03500263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active
Study NCT03500263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03500263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active
Study NCT03500263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active
Study NCT03424525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Trimethoprim
Description: \[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
Study NCT02762539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 enriched SMOF lipid emusion
Study NCT03646695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM flap transposition
Description: during ILM flap Transposition, an ILM flap is placed on the macular hole
Study NCT03646695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling
Description: during ILM Peeling the ILM is removed around the macular hole
Study NCT02652377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-494
Description: 10, 100 and 200 mg capsules
Study NCT02652377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-494
Study NCT03209050 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Central Venous Access Placement
Description: Device inserted into the femoral vein to insert a central venous access catheter
Study NCT02470611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alendronate
Description: After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% sodium alendronate gel
Study NCT02470611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% placebo gel
Study NCT01414556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic polypeptide
Description: infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
Study NCT01414556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline
Study NCT00570557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOR-BSST© Refresher Training
Description: Web-based refresher training in dysphagia screening
Study NCT02316847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazepam nasal spray
Study NCT02494752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat graft enriched with ex vivo expanded stem cells
Description: Fat graft will be enriched with ex vivo expanded stem cells
Study NCT02494752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fat graft not enriched with ex vivo expanded stem cells
Description: Fat graft will not be enriched with ex vivo expanded stem cells
Study NCT01265121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive air pressure device (CPAP)
Description: After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
Study NCT01265121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: External nasal dilator adhesive
Description: An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
Study NCT04225039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: 500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
Study NCT04225039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: 300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
Study NCT04225039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRS
Description: administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
Study NCT04225039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain surgery
Description: maximal safe surgical resection of the tumor.
Study NCT04335370 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~1. Prior to start of infusion~2. End of infusion~3. One hour after end of infusion~4. Three hours after end of infusion~5. Eight hours after start of infusion
Study NCT02127489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mL/kg bupivacaine 0.25%.
Description: 40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
Study NCT02127489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 mL/kg bupivacaine 0.25%.
Description: 40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
Study NCT03497780 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction
Description: Primary surgical reconstruction of the rupture anterior cruciate ligament
Study NCT02975297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
Study NCT02975297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT
Description: Nicotine Patch (21mg) / 24 hours.
Study NCT02975297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NRT
Description: Nicotine Patch (21mg) / 24 hours.
Study NCT02975297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Brief individual behavioral smoking cessation counseling.
Study NCT02975297 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: Brief individual behavioral smoking cessation counseling.
Study NCT02975297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline.
Study NCT02945007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 under fed or fasted conditions.
Study NCT00667186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Screening
Description: Selection method for screening is based on risk
Study NCT00667186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Screening
Description: Selection method for screening is not based on risk